ContextLogic Inc. (LOGC)

Overview

LogicBio Therapeutics, Inc. is a pioneering genetic medicine company established in 2014 with its headquarters in Lexington, Massachusetts. Specializing in the development and commercialization of advanced genome editing and gene therapy treatments, the company leverages its proprietary GeneRide and sAAVy platforms. These platforms are designed to deliver therapies for a variety of indications, targeting specifically gene-related diseases and conditions with significant unmet medical needs. Following a significant milestone on November 15, 2022, LogicBio became a subsidiary of Alexion Pharmaceuticals, Inc., marking a pivotal step in its journey toward bringing innovative genetic treatments to the market. Through strategic collaborations with renowned institutions and pharmaceutical companies like Children's Medical Research Institute, Takeda Pharmaceutical, CANbridge Care Pharma Hong Kong Limited, and Daiichi Sankyo Company, LogicBio is at the forefront of genetic medicine, driving forward the possibilities of gene therapy and editing for the betterment of patient care and treatment outcomes.

Products and Services

• GeneRide Technology

  GeneRide is an innovative gene therapy approach that utilizes the precise insertion of therapeutic genes into a patient's genome. This method leverages the natural mechanisms of deoxyribonucleic acid (DNA) to achieve targeted gene correction without using viral vectors for DNA delivery. The technology focuses on enhancing the body's own ability to repair and replace defective genes, potentially offering a cure for genetic diseases with a single treatment.

• sAAVy Gene Delivery Platform

  The sAAVy platform is an advanced adeno-associated virus (AAV) based system engineered to optimize the delivery of therapeutic genes. It allows for efficient and targeted gene delivery across a wide range of indications and tissues. This platform is crucial for the company's ability to address various genetic disorders by ensuring that therapeutic genes reach their intended destinations within the body safely and effectively.

• LB-001 for Methylmalonic Acidemia

  LB-001 represents LogicBio's leading product candidate, currently in Phase I/II clinical trials. This investigational therapy is geared towards the treatment of methylmalonic acidemia, a rare genetic disorder that affects the body's ability to break down certain fats and proteins, leading to a build-up of methylmalonic acid in the blood. By leveraging GeneRide technology, LB-001 aims to provide a groundbreaking treatment that could significantly improve the quality of life for patients suffering from this condition.

• Collaboration on Gene Therapy and Editing Applications

  LogicBio's collaborative efforts with Children's Medical Research Institute and Takeda Pharmaceutical Company Limited illustrate its commitment to advancing gene therapy and editing applications. These partnerships focus on developing next-generation capsids for gene delivery to the liver and other tissues, as well as the investigation of LB-301 for the treatment of Crigler-Najjar syndrome, showcasing the company's dedication to expanding its product pipeline and enhancing the therapeutic potential of genetic medicines.